# US 2015/0104520 A1 · Nanoparticle Formulations in Biomarker Detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104520 A1
- Document ID: US20150104520A1
- Status: Published application
- Kind: A1
- Application number: 14/246,366
- Filed: 2014-04-07
- Published: 2015-04-16
- Earliest claimed: 2013-04-05
- Inventors: Vuong Trieu; Larn Hwang
- Web page: https://patentgrep.com/patent/US20150104520A1

## CPC

- A61K 31/282: Platinum compounds
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compositions and methods of treatment of cancer patients with cytotoxic drugs in particular the use of cytotoxic drugs encapsulated in a diblock copolymer formulation where the composition is stable in protein free media and less stable in protein containing media such as serum, in particular the treatment of ovarian.

## Claims

### Claim 1

A method of treating patients with ovarian cancer comprising administering paclitaxel containing micelles and carboplatin to the patient.

### Claim 2 (depends on 1)

The method of claim 1 wherein the micelle is comprises of a diblock copolymer.

### Claim 3 (depends on 2)

The method of claim 2 wherein the paclitaxel containing micelles are IG-001.

### Claim 4 (depends on 3)

The method of claim 3 wherein the amount of paclitaxel administered is from about 220 mg/m2 to 300 mg/m2.

### Claim 5 (depends on 4)

The method of claim 4 wherein the amount of palitaxel administered is about 260 mg/m2.

### Claim 6 (depends on 5)

The method of claim 5 wherein the carboplatin is about 4-8 AUC.

### Claim 7 (depends on 6)

The method of claim 6 wherein the carboplatin AUC is about 5.

### Claim 8 (depends on 5)

The method of claim 5 wherein the paclitaxel containing micelles and carboplatin are administered in at least 6 cycles.

### Claim 9 (depends on 8)

The method of claim 8 wherein the paclitxel containing micelles and carboplatin are administered in 6 cycles over 3 weeks.

### Claim 10 (depends on 9)

The method of claim 9 wherein the overall response rate is greater than 70%.

### Claim 11 (depends on 9)

The method of claim 9 wherein the overall response rate is greater than 80%.

### Claim 12 (depends on 9)

The method of claim 9 wherein the overall response rate is greater than 90%.

### Claim 13 (depends on 9)

The method of claim 9 wherein the overall response rate is greater than 95%.

### Claim 14 (depends on 9)

The method of claim 9 wherein the overall response rate is about 70% to about 95%.

### Claim 15

A conditionally stable micelle composition containing an active compound wherein the composition is stable in protein-free medium and unstable in a protein containing medium.

### Claim 16 (depends on 15)

The conditionally stable micelle composition of claim 15, wherein the composition has a higher maximum tolerated dose.

### Claim 17 (depends on 15)

The conditionally stable micelle composition of claim 15, wherein the composition has improved intraperitoneal delivery.

### Claim 18 (depends on 15)

The conditionally stable micelle composition of claim 15, wherein the composition has expanded dose proportionality.

### Claim 19 (depends on 15)

The conditionally stable micelle of claim 15 wherein the micelle is comprises of a diblock copolymer.

### Claim 20 (depends on 15)

The conditionally stable micelle of claim 15 wherein the active compound is paclitaxel.

### Claim at position 21

21-50. (canceled)
